Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound.
The drugmaker said Thursday it will use the site, called LillyDirect, to pair visitors with third-party mail-order pharmacies for prescriptions and to care providers through a virtual medical weight-loss clinic.
The site also offers a directory for in-person care and help with insulins and migraine treatments.
Lilly says the doctors connected through the website are independent and not paid to promote its products, and the drugmaker also isn’t paid to send referrals to them.
In November, U.S. regulators approved Zepbound, a version of the popular diabetes treatment Mounjaro, to be used as a weight-loss treatment. The drug joins Novo Nordisk’s Wegovy in a hot field for care, chronic weight management.
At least 100 million adults are considered obese in the United States.
Indianapolis-based Lilly started its site to eliminate some of the complexity in the U.S. health care system that people face when they manage a chronic disease, Lilly CEO David Ricks said in a statement.
Drugmakers frequently offer coupons for their drugs or other help getting prescriptions, said Caitlin Donovan, a senior director for the non-profit Patient Advocate Foundation, which helps patients deal with serious or chronic health problems.
Pairing that prescription help with access to doctors in one location is unique, she added.
“Anything that’s going to streamline any type of process is good because we have the least streamlined healthcare system in the world,” Donovan said.
Telemedicine grew popular during the COVID-19 pandemic, and more companies have started offering virtual help directly to consumers for specific conditions, often through subscription plans. This trend has drawn concern from some doctors who see it simply as a push to sell more drugs.
Lilly says the care providers available through LillyDirect will use their own judgement in deciding treatment, and that may not include medication use.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
